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METHODS FOR BIOMOLECULE AND
BIOMOLECULE COMPLEX (BMC)
DETECTION AND ANALYSIS AND THE USE
OF SUCH FOR RESEARCH AND MEDICAL
DIAGNOSIS

assay solution. The particle size increase of the assay solution
was then monitored and used to identify the binding partner.
(B) Kinetic binding assay of EGFR-AuNP probe for mouse
IgGl-AuNP probe was used as a negative isotype control to
the EGFR-AuNP probe) with EGFRprotein and its complex
from a pancreatic cancer cell line, Pane-I nuclear extracts.
(C) and (D) Protein complex binding partner analysis
whereby the polyclonal anti-Stat3, anti-Src or anti-EGFR
antibody or the non-specific rabbit IgG (negative control) is
added to the assay solution prepared from the anti-EGFRAuNP probe (C) or non-specific mouse IgGl-AuNP probe
(negative control) (D). Data are representative of 4 independent studies.
FIG. 5 (A) An illustration of gold nanoparticle immunoprobe cluster formation due to their binding with protein
complexes or aggregates. (B) From the nonlinear dose-response curve, the concentration at which substantial GAPDH
protein aggregation appears is identified. (C) and (D) The
particle size distribution curves of the GAPDH assay solution
at 25 and 50 µg/mL, respectively.
FIG. 6 (A) The size distribution curves of assay solutions
from a normal prostate, prostate adenocarcinoma, and benign
prostate hypertrophy (BPH) tissue lysate sample. Data presented in each graph are intensity distribution curves of an
assay solution from ten measurements. (B) The polydispersity index (PdI) of the assay solutions from each sample. The
numbers on top of the prostate cancer sample data are the
Gleason sum score of the tissues. All data presented here are
the average often measurements.
FIG. 7 Mouse serum protein adsorption study and target
protein analysis. Data are particle size increases of the assay
solution of: (A) undiluted mouse serum adsorbed to AuNPs;
(B) IgG assay of 10-fold diluted mouse serum; (B) VEGF
assay of 10-fold diluted mouse serum. For each assay, 40 µL
ofAuNP solution was mixed with 2 µL of serum sample. After
certain incubation time, an appropriate amount of anti-mouse
IgG or anti-VEGF was added to the assay solution to analyze
the level of IgG or VEGF adsorbed to AuNPs.
FIG. 8 VEGF assay results of 10-fold diluted (A) and
undiluted (B) human serum samples from cancer and noncancerous donors. The non-cancerous donors include normal
and BPH patients. 40 µL of AuNP solution was mixed with 2
µL of serum sample. After certain incubation time, 2 µL
anti-VEGF solution(0.5 mg/mL)was added. The particle size
increase is the size difference measured before and after the
addition of antibody. In A, the small legends on some samples
such as Tic are the stage of the prostate cancer. Samples with
a cancer stage ofT2c or above are labeled with a cyan color.
The average particle size change of all cancer samples minus
the six early stage cancer samples is zero.
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CROSS-REFERENCE TO RELATED
APPLICATIONS
This application is related to U.S. Provisional Application
No. 61/294,877; filed Jan. 14, 2010 and U.S. Provisional
Application 61/407,038 filed Oct. 27, 2010, and to which
priority is claimed under 35 USC §119.

10

INTRODUCTION
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Biomolecular interactions such as protein-protein and protein-DNA interactions play an essential role in almost all
cellular functions. Many intracellular biochemical processes
are triggered by the assembly of biomolecules including proteins, DNAs and RNAs into biomolecule complexes (BMC),
providing a means to control the myriad of biochemical processes for the efficient management of vital biological
responses. The detection and analysis of these biomolecule
complexes is not only critical for understanding the mechanisms of diseases, but also provide new methods and
approaches for diagnosis and treatment of the diseases.
While a large number ofbioanalytical techniques exist for
detecting and analyzing the concentrations of individual biomolecules, techniques available for studying biomolecular
interactions and for biomolecule complex detection and
analysis are rather limited and inadequate to meet the
demands and challenges ofbiomolecular research and medical diagnosis. Many traditional techniques such as co-immunoprecipitation, immunoaffinity chromatography, and yeast
two-hybrid assays involve complicated assay procedures,
require a large volume of samples (1 OOs µL ), and take hours
to days to obtain the results. Furthermore, these traditional
techniques can only reveal the identities of the binding partners, and are not capable of providing the kinetic binding
information. More recent techniques, such as fluorescencebased techniques and surface plasmon resonance (SPR)
enable both detection and kinetic binding study of biomolecular interactions and complex formation, but have limitations, such as labeling, that may affect or destroy the structure
and binding activity of the biomolecules, or in the case of
SPR, theneedfor a solid-phase based technique (not solutionbased assay) and the high cost.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 shows a schematic of a first embodiment of a target
molecule detection system.
FIG. 2 shows a schematic of a second embodiment of a
target molecule detection system.
FIG. 3 shows a schematic of a third embodiment of a target
molecule detection system.
FIG. 4. (A) An illustration of an assay for protein complex
detection and binding partner analysis from a cell nuclear
extract. The assay was comprised of two steps: in the first
step, AuNP immunoprobe for one target protein, here is
EGFR, is mixed with a sample solution. The particle size
increase caused by the binding of EGFR protein or protein
complex to AuNP probes is monitored. After the binding
event reaches an end point, the assay solution was divided into
multiple portions and to each portion, a polyclonal antibody
for each suspected protein binding partner was added to the
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The present patent application discloses several new methods to detect and analyze biomolecule complexes (BMC) and
use of such for medical diagnosis. For the purpose of this
application, biomolecule complex is defined as one biomolecule subunit such as proteins, DNAs, RNAs, carbohydrates
bound with at least another biomolecule through covalent or
non-covalent chemical bonding. An individual biomolecule
or biomolecule subunit is defined as a monomer. Furthermore, two types of biomolecule complexes are specifically
exemplified here: one is heterogeneous complex made from
one biomolecule and at least another different biomolecule,
and a second one is a homogenous complex made from at
least two same biomolecules or biomolecule subunits. Also
for the purpose of this application, each molecule component

US 9,005,994 B2
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in the complex is defined as "binding partner". This application mainly uses proteins as an example of biomolecules,
however, the methods disclosed here can be applied for any
other types of biomolecule complexes such as protein-DNA,
protein-RNA, DNA-DNA, DNA-RNA complexes. Naturally,
the embodiments disclosed herein may be used to detect
biomolecules that are not complexed or aggregated.
For the purpose of this application, nanoparticles in this
application refer to particles with a diameter ranging from 1
nm to 10,000 nm, preferably 1-1000 nm. The new methods
and system embodiments disclosed herein are an extension of
the ground breaking work disclosed in PCT/US09/30087;
filed Jan. 5, 2009.
It should be borne in mind that the type of nanoparticle
referred in the present patent application is not limited to
metal nanoparticles. The particle size measurement technique in this application is not limited to dynamic light scattering. Furthermore in some embodiments as described
below, other detection techniques may be used to detect the
nanoparticle clustering caused by biomolecular complex
interactions.
Biological samples that can be tested using the method
embodiments taught herein include, but are not limited to, are
tissue, tissue lysates, tissue fluids, cells, cell lystates, cell
culture media, blood, urine, stool, semen, fluid secreted from
breast, saliva, sputum, or circulating tumor cells; and/or products derived from the above biological samples after chemical, physical, or biological treatments. Reference to diseased
or non-diseased samples herein refers to biological samples
in or derived from a subject having a disease state or a nondiseased state, respectively.
FIGS. 1-3 provide schematics of three embodiments for
detecting biomolecules. In one embodiment (FIG. 1), the
invention involves a nanoparticle (preferably gold or silver
nanoparticle) that is coated with a layer of "baiting" biomolecule. A "baiting molecule" as used herein means a molecule
that can specifically bind with another biomolecule through
non-covalent chemical interactions. Antibody is an example
of"baiting molecule". Single strand DNA is another example
of a "baiting molecule". The baiting molecule will bind with
a specific target molecule X in the sample. This baiting molecule-coated nanoparticle is referred to herein as "nanoparticle probe". By contacting the nanoparticle probe solution
with a sample solution, a target molecule X and/or its complexes will bind with the nanoparticle probe, causing nanoparticle probe size increase or nanoparticle clustering. Such
nanoparticle size change in the assay solution can be measured by dynamic light scattering or other particle size analysis techniques to reveal the presence of target protein or
protein complexes in the sample solution. The size measurement can be done continuously to reveal the binding kinetics
as illustrated in the graph in FIG. 1. The binding constant or
binding energy between the baiting molecule and the target
molecule or complex can be obtained by fitting the binding
curve into a Langmuir adsorption model using Langmuir
equation. When the binding reaches a saturated level, the size
of the target molecule X and/or its complex may be revealed
from the average particle size change or particle size distribution change. The particle size change can be used to obtain
the concentration of molecule X in the sample solution. Furthermore, by designing the assay so that a saturated binding
between molecule X and the nanoparticle probe is achieved,
the net increase of the particle size at saturated binding should
be equal to twice of the diameter (2D) of the target molecule
X. From this analysis, the size of molecule X can be obtained.
If target molecule X formed complexes with other biomolecules, then the nanoparticle size increase will exceed the 2D

value of X. In this case, the obtained size information of
molecule X can be used to deduce the complex status and
level of molecule X.
As a variation to this embodiment, the same nanoparticle
could contain more than one type of baiting molecules for
different target molecules. For example, baiting molecule for
X and A can be both immobilized on the nanoparticle and
such nanoparticle can bind with more than one type of target
molecule from sample solution.
Furthermore, by adding a second step to the assay, the
binding partner of the biomolecular complex can be further
revealed through a screening analysis. After the first step of
the assay, a solution of baiting molecule that can specifically
bind with an interested binding partner molecule A will be
added to the assay solution. The nanoparticles may or may not
need to be isolated from the rest of the assay solution before
conducting the second step of the assay. If the interested
potential binding partner A is present on the nanoparticles, the
binding of the baiting molecule for target molecule A to the
nanoparticle will cause a further increase of the nanoparticle
size or nanoparticle cluster formation, therefore, confirming
that molecule A and molecule X formed a biomolecular complex.
Alternatively, the method can include the successive exposure of the assay solution to baiting molecule for target moleculeA without conducting particle analysis after exposure to
the nanoparticle probe with the biological sample. Based on
the particle characteristics, one can determine whether baiting molecule for target molecule A binds to the nanoparticle
probe presumably already having target molecule X bound
thereto. From this, it can be deduced that the biomolecule
complex includes target molecule X complexed to target molecule A.
In a second embodiment (FIG. 2), the assay is designed so
that same or different nanoparticle probes will bind with a
biomolecule complex from different sites of the complex to
form nanoparticle clusters. In the illustration, two nanoparticle probes for two biomolecules X and A are shown. For
illustration purpose, the complex shown here is a two-molecule complex, but the complex can include as many molecules as possible. The two nanoparticle probes may be mixed
simultaneously or sequentially with the sample solution.
When used simultaneously, the assay will lead to nanoparticle
dimer or cluster formation if a biomolecule complex XA is
present in the sample solution. The average particle size and/
or particle size distribution will provide quantitative information on the complexing level of XA. Complexing level can
mean both concentration of the complex XA and the size of
the complex. For example, the presence oflarge biomolecule
complex will lead to significant broadening of the particle
size distribution curve. When used sequentially, either nanoparticle probe may be first mixed with sample solution to
allow binding of the first biomolecule from the complex to the
nanoparticle pro be. Then a second pro be is added to detect the
second biomolecule in the complex. More nanoparticle
probes may be added to the assay solution to detect additional
binding partners in the complex.
As a special case of second embodiment, target molecule X
and A are the same. In this case, biomolecular complex XA
may also be called bimolecular aggregate (or may also be
referred to as a homogenous complex).A larger aggregate can
lead to larger particle size increase and/or broadened particle
size distribution curve after the sample solution is in contact
with at least one nanoparticle probe solution.
Reference to particle analysis may include, but is not limited to, determining a particle size change (including an individual particle size change), an average particle size change,
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particle size distribution change, polydispersity change of the
size distribution, or measurement-to-measurement particle
size variation, or combinations thereof. In a specific embodiment, particle analysis is conducted via DLS.
In a third embodiment, a nanoparticle without specific
baiting molecule attached on the surface is mixed with a
sample solution. Proteins and/or other biomolecules from the
sample solution will be non-specifically adsorbed to the
nanoparticle to form a biomolecule "corona". Gold or silver
nanoparticles possess a charge that will allow them to nonspecifically adsorb biomolecules. The size of this biomolecule corona, may be determined using dynamic light scattering or other suitable particle size analysis techniques. The
size of this corona may be used to analyze a biological process, determine the disease status or reveal other physiological conditions of the sample donor. Furthermore, a second
step assay may be conducted to reveal and quantify the individual biomolecules that are present in the biomolecule
corona. If a target molecule X is present in the corona, the
addition of an antibody or baiting molecule for molecule X to
the assay solution will further increase the size of the particle,
or cause particle cluster formation. Such particle size change
can be correlated to the concentration or the size of molecule
X in the sample solution. The concentration and/or size information of X can be used to analyze a biological process,
determine the disease status or reveal other physiological
conditions of the sample donor. Alternatively, if a target molecule D is not adsorbed to the nanoparticle, then the addition
of a baiting molecule for Din the assay solution will not cause
significant change of the nanoparticle size or formation of
nanoparticle clusters.

this complex functions as a transcript factor to regulate the
cell growth of Pane- I. An assay based on the first embodiment
confirmed the existence of such a complex in Pane- I cell
nuclei.
A mouse monoclonal antibody, anti-EGFR, was conjugated toAuNPto formEGFR-AuNPprobe. Upon mixing this
probe solution with Pane-I nuclear lysate, the particle size
increased rapidly from ca. 60 nm to 140 nm, while a nonspecific isotype control mouse IgG I-conjugated to AuNP
exhibits only about I 0 nm of size increase after the assay
(FIG. 4B). The rapid increase of the nanoparticle probe size
corresponds to specific binding of target protein EGFR to the
probe, while the slow and small size increase of mouse IgG 1AuNP probe is indicative of non-specific interactions.
The net increase of the anti-EGFR-AuNP probes after
deducting the size increase caused by non-specific interactions, is about 70 nm. This suggests that the size of the EGFR
protein complex detected by the anti-EGFR-AuNP probe is
approximately 35 nm. EGFR protein has a molecular mass of
170 KDa. The size ofEGFR protein alone should be between
I 0-45 nm. Therefore, data shown in FIG. 4B suggests that the
EGFR detected by the nanoparticle probe is most likely in a
complex form. In a second step assay, when a polyclonal
anti-Stat3 or anti-Src was added to the assay solution, the
nanoparticle size increased further by 30-35 nm; while the
addition of isotype control rabbit IgG and anti-EGFR caused
much less nanoparticle size increase (FIG. 4C). The substantial size increase from the addition of anti-Stat3 and anti-Src
suggests that Stat3 and Src are binding partners in the EGER
complex. The small size increase of the assay solution upon
addition of anti-EGFR probe is due to the fact that Stat3 and
Src in the complex blocked the binding sites ofanti-EGFR to
the nanoparticle-bound EGFR protein. The EGFR/Stat3/Src
complex was further confirmed by co-immunoprecipitation
followed by immunoblotting and laser scarming confocal
microscopic analysis.
Co-immunoprecipitation is considered as the gold standard for protein complex detection from biological samples.
However such analysis requires a substantial amount of
samples (IOOs µL) and the analysis takes hours to days to
complete. SPR technique also requires I Os- I OOs µL of sample
per analysis. As a comparison, our new assay requires 1-2 µL
of lysate samples and results are obtained in minutes. More
importantly, neither co-immunoprecipitation, nor fluorescence technique, nor SPR is able to reveal the size information of the EGFR-Stat3-Src complex. Such information is
particularly useful for protein complex analysis: it gives the
first evidence of the presence of a protein complex, and can
further reveal how many binding partners are involved in a
protein complex. According to the assay results obtained so
far, we believe the complex involves EGFR, Stat3 and Src
only, because the estimated hydrodynamic diameter of such a
triple-component complex according to each protein's size is
around 35 nm, corresponds to the observed size from the
assay.
2. Protein Aggregate Detection and Quantitative Analysis
Protein aggregate formation is a significant and challenging problem in biopharmaceutical development. To use proteins as therapeutic agents, they need to be formulated into
high concentration solutions. Unfortunately, many proteins
tend to aggregate at high concentrations. Once protein is
aggregated, it can cause significant adverse effects by changing the pharmacokinetics of the drug or inducing unexpected
immunogenicity. Protein aggregation is also closely associated to many diseases such as prion protein aggregates in
Creutzfeldt-Jakob disease (CJD) and amyloid ~-protein
aggregates found in Alzheimer's disease. However, tech-
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EXAMPLES
In the following, three examples are given for each of the
embodiments as described above. Additionally, a fourth
example is provided to describe how the biomolecular complexes discovered from our research can be used for diagnostic applications.
I. Detection of a Heterocomplex EGFR/Stat3/Src From a
Pancreatic Cancer Cell Line, Pane- I Cells
Using the first embodiment (FIG. 1), we recently successfully studied the assembly of signaling molecules into complexes that promote signal transduction. In particular, the new
invention permitted the detection of hitherto unknown heterocomplex formed from three proteins: epidermal growth
factor receptor (EGFR), Stat3, and Src in the nuclei of a
pancreatic cancer cell line, Pane- I. EGFR is an important
regulator of cellular responses, including growth and survival. The attention from biomolecular researchers on EGFR
protein has been enormous in part because there remains a
significant gap in the understanding of the key molecular
partners that serve this pathway and how they contribute to
the overall associated cellular responses. From the molecular
and biological perspectives, EGFR is involved in a large
number of sophisticated events that support cellular processes. EGFR is found in the plasma membrane, cytosol and
nuclei of cells. A full understanding of all aspects of the
EGFR protein, not only its expression level, but also its activity regulation, translocation, structural changes and the interactions with other proteins is essential for developing an
effective model relevant to the functional role of this pathway
in the overall biological phenotype. A study by J. Turkson et
al. revealed that concurrent targeting of three proteins, EGFR,
Stat3 and Src can enhance the therapeutic effect on pancreatic
cancer. It was hypothesized based on their studies that EGFR,
Stat3 and Src may have formed a heterocomplex nuclei and
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niques that are available for direct detection and analysis of
and the potential link of such differences with cancer status of
protein aggregation are extremely limited, especially for the
a biological system was discovered.
detection of protein aggregates from complex biological
3. Serum Protein and Protein Complex Detection and Prosamples and fluids in the presence of non-target proteins,
filing for Diagnosis
biomolecules, and other colloidal particles. One widely used
Using the third embodiment as illustrated in FIG. 3, we
approach is by fluorescence techniques. Fluorescent probes
discovered some very interesting and intriguing molecular
are conjugated to the target protein by covalent bonding.
differences between serum samples with and without prostate
cancer from both mice models and human donors. Prostate
Upon protein aggregation, fluorescent probe molecules will
cancer is one of the most prevalent types of cancer in men. It
also aggregate, causing fluorescence signal change. A significant drawback of the fluorescence techniques is the need to do 1o is estimated that 217, 730 men will be diagnosed with and
a fluorescence labeling of the target molecule. Other com32,050 men will die of prostate cancer in 2010. Despite the
monly used techniques for protein aggregate detection
enormous research efforts and investigations, early detection
include size exclusion chromatography (SEC) and analytical
and diagnosis of prostate cancer has remained a significant
ultracentrifugation. These techniques are only suitable for
challenge in medicine due to multiple complicated factors.
pure protein solution study, not suitable for detection of pro- 15 PSA test, a test that measures the level of prostate specific
antigen in blood, has been widely used in the United States in
tein aggregates and complexes directly from real biological
samples.
the last two decades for initial screening of prostate cancer.
We have demonstrated that a new assay as illustrated in the
However, several recent studies have led to significant doubts
second embodiment (FIG. 2) can be used as a label-free
on the efficacy of PSA test. Over-diagnosis and treatment of
technique for highly sensitive detection of protein aggregates. 20 low-risk prostate cancer has serious and long-lasting side
effect: 33% of the patients who receive radical prostatectomy
In Rayleigh scattering, the scattered light intensity is proportional to the sixth power of the radius (I cxR 6 ) of a particle.
treatment will suffer erectile dysfunction that cannot be remWhen protein complexes or aggregates with a non-uniform
edied by drugs such as Viagra. New biomarkers and test
size distribution are present in a sample solution, these commethods that can reliably distinguish prostate cancer from
plexes/aggregates will load to the formation of large nano- 25 benign conditions and slow growing tumor from high risk
particle clusters as shown in FIG. SA. The scattered light
cancer are of tremendous value in prostate cancer diagnosis
intensity from the large AuNP clusters is thousands to miland treatment.
lions times stronger than individual AuNPs (the detection
Three mice models were used for this study: one was
limit for individual AuNPs by DLS can already reach pM-aM
orthotopically injected with a fast growing prostate cancer
range). Protein aggregation can be detected with extremely 30 cell line PC3; one with a slow growing tumor cell line LnCaP;
high sensitivity through the amplification of AuNP probes.
and a third group of mice injected only with PBS saline
Results shown in FIG. SB-D are from our study on an enzyme
solution as control. FIG. 7 are the analysis results of mice
GAPDH (glyceraldehyde 3-phosphate dehydrogenase, a proserum samples. First, there is a dramatic difference in the
"size" of the proteins or protein complexes adsorbed from
tein used routinely as a loading control in Western Blot analysis). From the assay, we discovered that this protein has a 35 serum to AuNPs (FIG. 7A). The particle sizes from mice with
strong tendency to form large aggregates at a concentration
large and fast growing tumor from PC3 cells are substantially
around 10-25 µg/mL. The protein aggregate formation leads
smaller than that from normal healthy mice and mice with
to a non-linear and abnormal nanoparticle size increase
small and slow growing tumor from LnCaP cells. When the
around this concentration (FIG. SB), and significant broadserum samples were diluted 10-fold and the serum protein
ening or even peak splitting of the size distribution curves 40 adsorption assay was repeated, all samples exhibited similar
(Compare FIG. SD with FIG. SC).
particle size increase of 15-18 nm after the assay.
Furthermore, by using this new assay, we discovered that a
The inventor then analyzed two target proteins: one is an
cancer biomarker protein, prostatic acid phosphatase (PAP)
abundant protein, mouse IgG, and another one is a well
exists more in the form ofbiomolecular complexes in cancer
known cancer biomarker protein, VEGF (vascular endothetissue than in normal and benign prostate hyperplasia (BPH) 45 lial growth factor) according to the assay process as illustissue. For this assay, an anti-PAP antibody is conjugated to
trated in FIG. 3. Again, some interesting differences were
AuNPs to make a nanoparticle immunoprobe. As shown in
observed from these two assays. In the IgG assay, mice with
FIG. 6A, the particle size distribution curves from prostate
small tumor grown from LnCaP cells exhibit higher level of
IgG than the other two groups (FIG. 7B). In the VEGF assay,
cancer tissue lysate assay solution are substantially more
broadened than BPH samples, and a significant amount of 50 the normal healthy mice exhibit significantly higher level of
large nanoparticle clusters appeared at 1OOs nm size range.
AuNP-adsorbed VEGF than the mice with prostate cancer
Such broad particle size distribution and the appearance of
(FIG. 7C). Intrigued by the results observed from mice model
study, we examined human serum samples obtained from
large nanoparticle clusters are explained by the presence of
subjects with prostate cancer. Three groups of human serum
PAP protein in the form oflarge biomolecular complexes or
aggregates. The level of particle size distribution curve broad- 55 samples were studied: normal healthy donors; patients diagerring can be quantitatively expressed using a polydispersity
nosed with benign prostate hyperplasia (BPH); and patients
index (PdI). As shown in FIG. 6B, the PdI of assay solutions
diagnosed with prostate cancer (stages Tic to T3b ). From the
obtained from prostate cancer tissue lysates is clearly higher
VEGF assay, same difference was observed from the cancer
than the assay solutions of normal prostate and BPH tissue
versus non-cancer samples (normal donor and BPH patients)
lysates. Interestingly, BPH tissue lysate assay solutions 60 (FIG. 8): the non-cancer samples show higher level ofAuNPexhibit a narrower particle size distribution than normal tissue
adsorbed VEGF level than the prostate cancer samples. T-test
lysates, indicating that a different molecular mechanism is
analysis of the assay data gave a p-value of 0.001 for both
diluted and undiluted human serum samples, indicating that
involved in BPH than in prostate cancer. Furthermore, it
the difference between cancer and non-cancerous samples
appears that more advanced prostate cancer with higher Gleason scores leads to a higher complexing level of PAP protein. 65 was statistically significant. Furthermore, it was found from
To our best knowledge, this is the first time that such molecuthe assay that the AuNP-adsorbed VEGF level is also cancer
lar profile differences were revealed from biological samples
stage-dependent: the more advanced prostate cancer exhibits
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lower VEGF level than the early stage prostate cancer. Early
stage prostate cancer such as Tlc shows similar VEGF level
as healthy donors. In conclusion, the analysis of both mice
model and human donor samples revealed that the amount of
AuNP-adsorbed VEGF is decreased in cancer serum samples.
This discovery could potentially lead to a new blood test with
improved accuracy for prostate cancer detection. Furthermore, by screening other proteins or bimolecular targets
using this assay, it is expected that additional protein or biomolecular biomarkers that are unique to cancer and other
human diseases can be discovered. This new assay established in our recent work may be used as a general tool for
serum protein biomarker discovery.
4. The Use ofBiomolecular Complexes as Biomarkers for
Diagnostic Applications
There are several types ofbiomarkers that have been identified so far and can be used for prostate cancer detection and
diagnosis, particularly, for distinguishing prostate cancer
from non-malignant conditions such as BPH: (1) The
increased complexing level of PAP protein in tissue and
bodily fluids; (2) The decreased level of VEGF protein in
blood samples. This VEGF protein is referred to VEGF protein that is adsorbed to a nanoparticle through complexing
with other proteins or biomolecules present in the blood
serum; (3) The size of the biomolecule corona formed on a
nanoparticle surface after non-specific adsorption ofbiomolecules from a biological sample to the nanoparticles.
The claims for biomarkers may be extended to the detection and diagnosis of other diseases and conditions: (1) The
size of the biomolecule corona formed on a nanoparticle
surface after a non-specific adsorption of biomolecules from
a biological sample to the nanoparticles; (2) The size of the
biomolecule corona formed on a nanoparticle surface after a
specific binding of biomolecules from a biological sample to
the baitingmolecule-conjugatednanoparticles; (3) Individual
molecule component or biomolecule complexes of the biomolecule corona formed on a nanoparticle surface after a
non-specific adsorption or specific binding of biomolecules
from a biological sample to the nanoparticles that show significant difference between diseased and non-diseased
samples.

tering. SPIE Proceedings, (2010), 7674 (Smart Biomedical
and Physiological Sensor Technology), 767 408/1-7 67 408/
9.
7. Bogdanovic, J.; Colon, J; Baker, C.; Huo, Q. A label-free
nanoparticle aggregation assay for protein complex/aggregate detection and analysis. Anal. Biochem. 2010, 405,
96-102.
8. Huo, Q. Protein complexes/aggregates as potential cancer
biomarker revealed by a nanoparticle aggregation immunoassay. Colloids SurfB. 2010, 78, 259-265.
9. Jaganathan, S.; Yue, P.; Bogdanovic, J.; Huo, Q.; Turkson,
J. A functional nuclear epidermal growth factor receptor,
Src and Stat3 heteromeric complex in pancreatic cancer
cells. Plos One, 2010, submitted.
10. Huo, Q.; Cordero, A.; Bogdanovic, J.; Colon, J.; Baker, C.
H.; Goodison, S.; Pensky, M. A facile nanoparticle immunoassay to detect multiple biomarkers in serum samples.
Nanomedicine: Nanotechnology, Biology and Medicine,
2010, submitted.
It should be borne in mind that all patents, patent applications, patent publications, technical publications, scientific
publications, and other references referenced herein are
hereby incorporated by reference in their entirety to the extent
not inconsistent with the teachings herein.
Reference to particular buffers, media, reagents, cells, culture conditions and the like, or to some subclass of same, is
not intended to be limiting, but should be read to include all
such related materials that one of ordinary skill in the art
would recognize as being of interest or value in the particular
context in which that discussion is presented. For example, it
is often possible to substitute one buffer system or culture
medium for another, such that a different but known way is
used to achieve the same goals as those to which the use of a
suggested method, material or composition is directed.
It is important to an understanding of the present invention
to note that all technical and scientific terms used herein
unless defined herein, are intended to have the same meanin~
as commonly understood by one of ordinary skill in the art.
The techniques employed herein are also those that are known
to one of ordinary skill in the art, unless stated otherwise. For
purposes of more clearly facilitating an understanding the
invention as disclosed and claimed herein, the following definitions are provided.
While a number of embodiments of the present invention
have been shown and described herein in the present context,
such embodiments are provided by way of example only, and
not of limitation. Numerous variations, changes and substitutions will occur to those of skilled in the art without materially departing from the invention herein. For example, the
present invention need not be limited to best mode disclosed
herein, since other applications can equally benefit from the
teachings of the present invention. Also, in the claims, meansplus-function and step-plus-function clauses are intended to
cover the structures and acts, respectively, described herein as
performing the recited function and not only structural
equivalents or act equivalents, but also equivalent structures
or equivalent acts, respectively. Accordingly, all such modifications are intended to be included within the scope of this
invention as defined in the following claims, in accordance
with relevant law as to their interpretation.
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What is claimed is:
1. A method for detecting a biomolecule complex in a
biological sample, said method comprising
producing a first assay product by contacting a biological
sample with a first nanoparticle probe, said first nano-
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particle probe comprising a nanoparticle bound to a first
baiting molecule specific to a first target molecule of
interest;
contacting the first assay product with a second baiting
molecule specific to a second target molecule of interest
to produce a second assay product; and
detecting by particle analysis for presence of nanoparticle
probe bound to said first target molecule of interest, or
for presence of said second target molecule of interest in
said second assay product, or both, wherein if both, a
complex of the first and second target molecules is
present in the biological sample.
2. The method of claim 1, wherein particle analysis comp?ses determining a particle size change, an average particle
size change, particle size distribution change, polydispersity
change of the size distribution, or measurement-to-measurement particle size variation, or combinations thereof.
3. The method of claim 1, wherein said particle analysis is
by dynamic light scattering analysis.
4. The method of claim 1, wherein the particle analysis
c.omprising determining a particle size change over nanopart1cle probe-sample incubation time or over first target molecule concentration is used to obtain the binding constant or
binding energy between the first baiting molecule and the first
target molecule.
5. The method of claim 4, wherein the binding constant or
binding energy is obtained by fitting the binding data into a
Langmuir adsorption model.
6. The method of claim 1, further comprising determining
whether a first target molecule is a monomer based on particle
analysis.
7. The method of claim 6, further comprising determining
the quantity of a biomolecule complex based on particle
analysis; or determining the size of a biomolecule complex
based on particle analysis.
8. The method of claim 7, further comprising utilizing a
quantity of a biomolecule complex to analyze a biological
process, or for detection, diagnosis and/or prognosis of a
disease; or utilizing the size of a biomolecule complex to
analyze a biological process, or for detection, diagnosis and/
or prognosis of a disease.
9. The method of claim 8, wherein the disease is cancer.
10. The method of claim 6, wherein the biomolecule complex is a complex of PAP (prostatic acid phosphatase).
11. The method of claim 1, wherein said biomolecule complex comprises at least one first biomolecule or first biomolecule subunit associated with at least one other biomolecule.

12
12. The method of claim 11, wherein said at least one other
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biomolecule is the same as the first biomolecule or first biomolecule subunit.
13. The method of claim 1, wherein said detecting comp?ses subjecting said second assay product to particle analysis.
14.A method for detecting a target molecule in a biological
sample, said method comprising
(a) obtaining a first assay product that has been produced
by contacting a biological sample with a first nanoparticle probe, said first nanoparticle probe comprising a
nanoparticle bound to a first baiting molecule specific to
a first target molecule of interest;
(b) .subjecting said first assay product to a second nanopart1cle probe comprising a second baiting molecule that is
specific to a second target molecule of interest to produce a second assay product; and
(c) detecting for presence of second nanoparticle probe
bound to said second target molecule of interest in said
second assay product, wherein if the second nanoparticle probe bound to said second target molecule of
interest is detected, the second target molecule of interest is present in the biological sample; and further comprising detecting presence of first nanoparticle probe
bound to said first target molecule of interest in said first
assay product before step (c ), wherein a biomolecule
complex of said first and second target molecules of
interest is detected based on a difference in size between
said first assay product and said second assay product.
15. A method for detecting at least one biomolecule in a
biological sample, said method comprising obtaining a first
assay product produced by contacting a biological sample
with a nanoparticle, wherein said contacting forms a biomolecule corona on the nanoparticle surface, and conducting
particle analysis of the first assay product; and further comprising (i) using biomolecule corona size information for
detection, diagnosis and/or prognosis of a disease by comparing the biomolecule corona size information with size information from a known sample, or (ii) contacting said first assay
product with a baiting molecule that binds specifically to a
target molecule of interest to form a second assay product,
and detecting the presence and/or quantity of the target molecule of interest by particle analysis.
16. The method of claim 15, wherein said analysis comprises size analysis of the biomolecule corona.
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